










































Acute Overexpression of Myc in Intestinal Epithelium
Recapitulates Some but Not All the Changes Elicited by Wnt/-
Catenin Pathway Activation
Citation for published version:
Finch, AJ, Soucek, L, Junttila, MR, Swigart, LB & Evan, GI 2009, 'Acute Overexpression of Myc in Intestinal
Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/-Catenin Pathway Activation'
Molecular and Cellular Biology, vol 29, no. 19, pp. 5306-5315. DOI: 10.1128/MCB.01745-08
Digital Object Identifier (DOI):
10.1128/MCB.01745-08
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Molecular and Cellular Biology
Publisher Rights Statement:
Copyright © 2009, American Society for Microbiology
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
MOLECULAR AND CELLULAR BIOLOGY, Oct. 2009, p. 5306–5315 Vol. 29, No. 19
0270-7306/09/$08.000 doi:10.1128/MCB.01745-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Acute Overexpression of Myc in Intestinal Epithelium Recapitulates
Some but Not All the Changes Elicited by Wnt/-Catenin
Pathway Activation
Andrew J. Finch,†# Laura Soucek,† Melissa R. Junttila, Lamorna Brown Swigart, and Gerard I. Evan*
Department of Pathology and UCSF Helen Diller Family Comprehensive Cancer Center, 513 Parnassus Avenue,
San Francisco, California 94143-0502
Received 13 November 2008/Returned for modification 28 January 2009/Accepted 17 July 2009
The Myc transcription factor is a potent inducer of proliferation and is required for Wnt/-catenin signaling
in intestinal epithelium. Since deregulation of the Wnt/-catenin pathway is a prerequisite for nonhereditary
intestinal tumorigenesis, we asked whether activation of Myc recapitulates the tumorigenic changes that are
driven by constitutive Wnt/-catenin pathway signaling following adenomatous polyposis coli (APC) inactiva-
tion. Using mice in which expression of MycERTAM, a reversibly switchable form of Myc, is expressed
transgenically in intestinal epithelium, we define the acute changes that follow Myc activation as well as
subsequent deactivation. Myc activation reversibly recapitulates many, but not all, aspects of APC inactivation,
including increased proliferation and apoptosis and loss of goblet cells. However, whereas APC inactivation
induces redistribution of Paneth cells, direct Myc activation triggers their rapid attrition. Moreover, direct Myc
activation engages the ARF/p53/p21cip1 tumor suppressor pathway, whereas deregulation of Wnt/-catenin
signaling does not. These observations illustrate key differences in oncogenic impact in intestinal epithelium
of direct Myc activation and indirect Myc activation via the Wnt/-catenin pathway. Furthermore, the in situ
dedifferentiation of mature goblet cells that Myc induces indicates a novel cross talk between the Wnt/-catenin
and Notch signaling pathways.
Intestinal epithelium is a highly proliferative tissue that is
constantly renewed through the processes of cell division, mi-
gration, and shedding. The epithelium is comprised of a crypt-
villus unit that contains four differentiated cell types: entero-
cytes, enteroendothelial cells, goblet cells, and Paneth cells.
These are all generated from pluripotent stem cell progenitors
that reside at either the base (4, 5) or the 4 position (17, 39,
49) within each crypt and feed a CD133 transit-amplifying
cell population (56) that drives the 3- to 5-day-long upward
migration of the enterocyte, enteroendothelial, and goblet cells
to the villus tip, where they are eventually shed. Accumulating
evidence suggests that the continuously proliferating lgr5
crypt cell is the cell of origin in those intestinal tumors driven
by aberrant signaling through the Wnt/-catenin pathway (3),
which constitute the great majority of colorectal cancers.
Two principal signaling pathways determine cell fate in the
intestinal epithelium: the Wnt/-catenin and Notch pathways.
The secreted Wnt glycoproteins bind transmembrane recep-
tors of the frizzled family, inhibiting the adenomatous poly-
posis coli (APC)/axin/CK1/glycogen synthase kinase 3b de-
struction complex that phosphorylates -catenin and signals its
degradation. -Catenin then accumulates and translocates to
the cell nucleus, where it forms an activating complex with the
TCF-4 transcription factor and regulates expression of a char-
acteristic set of targets (60) that includes the genes encoding
the Myc oncoprotein (16), cyclin D1 (59), and the canonical
intestinal crypt stem cell marker lgr5 (65). Signaling through
the Wnt/-catenin pathway, which is strongest in the crypt and
declines along a gradient to the villus tip, is required for main-
tenance and proliferation of both the crypt stem cell and ad-
jacent transit-amplifying compartments. Consistent with this,
nuclear -catenin is found only in the proliferative areas of the
crypts in normal intestinal epithelium (25). The Wnt/-catenin
pathway is also critical for the spatial disposition of the various
cell types within the crypt-villus unit, both Paneth cell matu-
ration and retention at the crypt bottom and, in association
with the ephrin receptors B2 and B3 (themselves encoded by
-catenin/TCF-4 target genes), distribution and migration of
epithelial cells along the crypt-villus axis (6, 7). Inhibition of
the Wnt/-catenin pathway, whether through ectopic expres-
sion of the Wnt antagonist Dikkopf-1 (43), by genetic deletion
(25), or by dominant negative inhibition of TCF-4 (61), leads
to a diminished intestinal stem cell compartment and greatly
reduced crypt proliferation. Conversely, constitutive signaling
through the Wnt/-catenin/TCF pathway effectively locks in-
testinal cells in a crypt progenitor-like phenotype, driving pre-
cocious proliferation and suppressing differentiation (61). De-
regulation of Wnt/-catenin signaling causally underlies almost
all nonhereditary colorectal carcinomas. In most cases, dereg-
ulation arises through mutations that inactivate the APC tu-
mor suppressor, a component of the obligate complex required
to degrade -catenin (45). However, a significant fraction of
tumors instead inactivate Axin1 or harbor mutations in the
serine residues of -catenin that glycogen synthase kinase 3
phosphorylates to trigger -catenin degradation (34). Which-
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ever happens, the result is accumulation of nuclear -catenin
and deregulation of the -catenin–TCF transcriptional pro-
gram (26), blocking differentiation and driving the relentless
cell expansion that underpins most colorectal cancers.
Both the Notch receptors and their Delta and Jagged ligands
are transmembrane proteins. Upon ligation, Notch proteins
are cleaved by -secretase to release an intracellular domain
(NICD) that complexes with the DNA-binding protein RBP-J
(58), displacing associated corepressors and activating expres-
sion of a set of target genes that include Hes1. Hes1 encodes a
basic helix-loop-helix (bHLH) transcription factor that, in turn,
represses expression of Math1, another bHLH protein that
would otherwise direct differentiation away from the entero-
cyte lineage toward the three principal Paneth, goblet, and
enteroendocrine secretory cell types. Selection out of these
three terminal cell fates is determined by interactions with
several other bHLH proteins, including neurogenin 3 (Ngn3)
(18), Gfi1 (55), and NeuroD (38). When Notch signaling is
inhibited, for example, by -secretase inhibitors, differentiation
defaults to the Math1-dependent secretory lineage, rapidly
resulting in a lethal intestinal goblet cell metaplasia (32). Con-
versely, Math1-deficient mutant mice lack all secretory cell
intestinal lineages (66). Substantial evidence indicates that the
Wnt/-catenin and Notch signaling pathways act together to
determine form and function along the crypt-villus axis (37).
Myc is a highly pleiotropic bHLHZip transcription factor
that coordinates the diverse intracellular and extracellular
transcriptional programs required for normal and tumor cell
expansion. Myc expression is deregulated in most human can-
cers. However, preternaturally high levels of Myc trigger apop-
tosis and activation of ARF/p53, two intrinsic tumor suppres-
sor programs that serve to constrain its oncogenic potential
(29). It may be for this reason that Myc is directly activated by
mutation (e.g., amplification and translocation) in only a small
proportion of cancer types and, even then, usually only in
more-aggressive variants that may already harbor deficits in
apoptosis and/or the p53 pathway. More commonly, deregu-
lated Myc expression in tumors appears to be a consequence of
its relentless induction by the wide variety of upstream onco-
genic signals that drive human tumorigenesis, including Wnt/
-catenin (61), Notch pathways (23), and receptor tyrosine
kinase signaling via Ras. Myc is required both for the normal
mitogenic actions of physiological Wnt/-catenin signaling in
promoting crypt proliferation in the intestine (35) and for the
dramatic architectural disruption, precocious proliferation,
and suppression of differentiation induced by Wnt/-catenin
deregulation (50). However, the surprisingly scant overlap
between Myc (http://www.myccancergene.org/site/mycTarget
DB.asp) and Wnt/-catenin/TCF-4 (60; http://www-leland
.stanford.edu/rnusse/wntwindow.html) target genes inti-
mates that Myc, while necessary, cannot be the sole down-
stream transcriptional effector of the Wnt/-catenin/TCF-4
pathway. Ascertaining the role played by Myc in intestinal
homeostasis is also complicated by its likely role as a target of
the Notch pathway, as has been shown for other epithelial (23),
as well as hematopoietic (40, 53, 64), lineages. It is also clear
that the intestinal Wnt/-catenin, Notch, and Myc pathways do
not function independently but are deeply intertwined. Not
only do both Wnt and Notch pathways activate Myc, but Wnt
signaling itself activates the Notch pathway in intestinal epi-
thelium through induction of the Notch ligand Jagged 1 (48),
while Myc has been shown to reinforce Wnt/-catenin signal-
ing by repressing the Wnt inhibitors DKK1 and SFRP1 (9) and
inducing the Wnt receptor Fzd9 (27).
To ascertain the specific role played by Myc within the in-
testinal epithelium, as well as to establish the extent to which
Myc can or cannot substitute for either Wnt or Notch signal-
ing, we transgenically targeted expression of the reversibly
switchable form of Myc, MycERTAM (28), to intestinal epithe-
lium. Using this model, we have addressed the following ques-
tions. (i) Does acute activation of Myc recapitulate the phe-
notype observed upon acute loss of APC? (ii) Are the changes
in differentiation observed upon Myc activation due to alter-
ations in the status of terminally differentiated cells or due to
changes at earlier stages of differentiation? (iii) What are the
consequences of subsequent deactivation of Myc for intestinal
epithelium that has already undergone Myc-driven changes?
MATERIALS AND METHODS
Transgenic mice. The villin-MycERTAM transgene was generated by fusing a
9-kb fragment of the villin promoter (44) with the MycERTAM open reading
frame (28) followed by a simian virus 40 polyA cassette. Vector DNA was
microinjected into male-embryo pronuclei, and three lines positive for the trans-
gene were isolated and propagated. MycERTAM was activated in intestinal epi-
thelium by daily intraperitoneal injection of 1 mg tamoxifen dissolved in a peanut
oil vehicle. All studies involving mice adhered to protocol number AN076148
and were approved by the University of California, San Francisco (UCSF),
Institutional Animal Care and Use Committee.
Immunohistochemistry. To identify cells in S phase, mice were injected intra-
peritoneally with 2 mol bromodeoxyuridine (BrdU) 3.5 h prior to sacrifice. For
histological analyses, tissue samples were harvested, immersed in Z-fix (Anatech
Ltd., Battle Creek, MI) overnight, dehydrated, and embedded in paraffin and
5-m sections were cut, which were then rehydrated and boiled in 10 mM sodium
citrate (pH 6.0) at low power for 5 min to recover antigens. Following citrate
retrieval (or EDTA retrieval, in the case of -H2.AX), primary antibodies—
including rabbit polyclonal antibodies to serotonin (5-hydroxytryptamine
[5-HT]), lysozyme (DakoCytomation), p53 (Vector), p21cip1 (BD Pharmingen),
Muc2 (Abcam), and -H2.AX (Upstate)—were applied in blocking buffer (2.5%
bovine serum albumin, 5% goat serum, 0.3% Triton X-100 in phosphate-buffered
saline) for 2 to 16 h. Incorporated BrdU and apoptotic cells were detected with
a BrdU detection kit II (Roche) and an Apoptag kit (Chemicon), respectively,
according to the manufacturers’ instructions. After each slide was washed, sec-
ondary antibodies (Molecular Probes) were applied in blocking buffer for 30 min.
Fluorescent-antibody-labeled slides were rinsed in phosphate-buffered saline and
mounted in Dako fluorescent mounting medium containing 1 g/ml Hoechst
stain. The terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end
labeling (TUNEL) signal colocalized with Hoechst nuclear counterstain, al-
though the latter was often irregular and weak due to pyknosis and nuclear
disintegration. Alcian blue (Poly Scientific, Bayshore, NY) was used according to
the manufacturer’s instructions. Fluorescent images were collected in the Lab-
oratory for Cell Analysis (UCSF Comprehensive Cancer Center) using an
LSM510 confocal microscope (Zeiss) or an Axiovert 100 inverted microscope
(Zeiss) equipped with a Hamamatsu Orca digital camera.
Quantitative real-time PCR. Total RNA was extracted from mouse tissues by
mechanical homogenization in TRIzol reagent (Invitrogen, Carlsbad, CA) fol-
lowed by phenol-chloroform isolation, as per the manufacturer’s protocol. cDNA
was synthesized from 1 g of DNase I (Invitrogen, Carlsbad, CA)-treated RNA
using iScript (Bio-Rad, Hercules, CA). Real-time quantitative PCR was per-
formed by the UCSF Comprehensive Cancer Center Genome Analysis core
facility. The p19ARF primer/probe sets used to detect the p19ARF mRNA tran-
scripts were as follows: 5AGA GGA TCT TGA GAA GAG GGC C3 (forward)
and 5GCA GTT CGA ATC TGC ACC3 (reverse) for primers and 5FAM-
AAT CCT GGA CCA GGT GAT GAT GAT GGG-36TAMSp as the probe,
where FAM is 6-carboxyfluorescein and 36TAMSp is tetramethyl-6-carboxyrho-
damine (31).
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RESULTS
Myc activation in intestinal epithelium leads to rapid and
lethal changes in tissue morphology. Elevated expression of
the Myc proto-oncogene is observed in approximately 50 to
70% of all colon adenocarcinomas, in most instances as a
direct result of precocious signaling through the Wnt/-cate-
nin/TCF pathway. To assess how aberrant activity of Myc di-
rectly contributes to the intestinal tumor phenotype, we gen-
erated mice expressing MycERTAM under the control of the
villin promoter, a regulatory element active in all intestinal
epithelial lineages. Immunofluorescence staining for the
ERTAM moiety confirmed MycERTAM transgene expression
throughout the intestinal epithelium (data not shown). Several
independent villin-MycERTAM transgenic lines were generated,
and all shared similar phenotypes. Hence, one was chosen for
further study.
Sustained ectopic activation of MycERTAM in villin-
MycERTAM mice induced lethargy, weight loss, poor grooming,
and morbidity within 3 to 5 days. Analysis of blood chemistry
after 3 days of Myc activation (data not shown) indicated a
marked decrease in blood urea nitrogen and phosphate, con-
sistent with starvation. Examination of the gastrointestinal
tract revealed a full stomach but grossly swollen small intes-
tines almost devoid of luminal content (Fig. 1A and B), indi-
cating that starvation was (i) likely due to a failure of intestinal
absorption rather than a failure to eat and (ii) consistent with
the morbidity known to accompany perturbations in intestinal
homeostasis (15, 66). Histological examination indicated that
ectopic activation of Myc in intestinal epithelium rapidly elicits
dramatic changes in tissue and cellular morphology. After only
1 day of Myc activation, the luminal spaces between villi were
markedly reduced, a trend that progressed over time accom-
panied by an increase in overall cellular mass (Fig. 1C to F).
Villi assumed a crypt-like morphology, similar to that observed
following acute deletion of APC (51). After 3 days of Myc
activation, the relative disposition of stromal and epithelial
compartments was profoundly disrupted, with the frequent
appearance of a stromal bulb (Fig. 1F to H) situated partway
up the villus, indicating that the epithelial layer had outgrown
its supporting stroma. We also observed frequent abnormal
epithelial cell morphology, with some cells displaying a swollen
cytoplasm that stained very weakly with eosin (Fig. 1G). We
guess that these gross changes in intestinal structure underlie
the impaired absorption and the starvation that Myc activation
induces in these mice.
Direct activation of Myc in intestinal epithelium induces
increased proliferation, induction of apoptosis, and changes in
secretory cell composition. Myc drives multiple intracellular
FIG. 1. Myc activation in intestinal epithelium elicits rapid morphological changes. Nontransgenic control (A) and villin-MycERTAM (B) mice
were treated with tamoxifen (tam) for 3 days and dissected (C to F). Intestinal swelling is clearly evident following 3 days of Myc activation.
Hematoxylin and eosin (H&E) analysis of villin-MycERTAM mice shows that Myc activation drives villi into a more crypt-like morphology. Regions
boxed in panel F are magnified in panels G and H. (G) Yellow arrowheads show morphologically abnormal epithelial cells. (H) An example of
epithelial overgrowth and detachment from the underlying stroma is detailed.
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programs, including proliferation, dedifferentiation, apoptosis,
and a shift to biosynthetic metabolism, as well as diverse ex-
tracellular programs associated with cell expansion, including
angiogenesis, stromal remodeling, invasion, and inflammation.
However, the net output of Myc activation is highly dependent
upon cell type, context, and level (36). Hence, direct activation
of Myc may not always recapitulate the effect of endogenous
Myc indirectly activated by an upstream signaling pathway.
Since Myc is the key effector responsible for aberrant intestinal
epithelial proliferation in response to deregulated -catenin
signaling (51), we asked whether Myc activity alone is sufficient
to elicit ectopic proliferation in intestinal epithelium. To do
this, Myc was activated for 24 h in villin-MycERTAM mice, and
its impact on the rate and extent of intestinal epithelial prolif-
eration was assessed by BrdU incorporation. Myc activation
significantly increased the percentage of crypt cells in S phase
(BrdU positive), from 35%  3.7% to 71.2%  4.2% after 1
day and to 79.7%  4.3% after 2 days (Fig. 2A to C). Further-
more, the proliferative zone, as evidenced by both S-phase and
mitotic cells, rapidly extended up along the villus shaft. Of
note, a similar, although less dramatic, proliferative enhance-
ment was observed in the large intestine, where the villin pro-
moter is also active (data not shown).
To assess induction of apoptosis by Myc in intestinal epithe-
lium, we used TUNEL. Only occasional TUNEL-positive
apoptotic cells were evident in control tissue, as expected (Fig.
2D). However, significant apoptosis was evident within 1 day of
Myc activation (Fig. 2E) and thereafter maintained (Fig. 2F).
Most apoptosis was confined to the crypts, overlapping with
the most highly proliferative cells.
In various tissues, Myc is a downstream effector of both the
Wnt and Notch pathways, each of which has distinct effects on
differentiation within the intestinal epithelial compartment. To
assess the direct impact of Myc activation on intestinal epithe-
lial differentiation, we assessed the relative proportions and
locations of each differentiated cell type. Alcian blue stains
mucopolysaccharide-rich goblet cells, revealing the expected
periodic distribution throughout the crypt-villus compartment
in control tissue (Fig. 3A). Myc activation induced rapid, dra-
matic, and synchronous reductions in the number and intensity
of Alcian blue-staining cells throughout the epithelial layer,
with their effective disappearance within 2 days (Fig. 3B and
C). Likewise, in the colon, where goblet cells are yet more
prevalent, we observed rapid and synchronous loss of Alcian
blue staining throughout the crypts (Fig. 3D to F). The syn-
chrony of goblet cell loss, together with the fact that we never
observed any goblet cell apoptosis (and, anyway, apoptosis is
largely restricted to the crypts) suggests that Myc-induced loss
of goblet cells is a consequence of in situ dedifferentiation or
transdifferentiation, not cell death. This acute loss of goblet
cells probably underlies the dramatic starvation phenotype in-
duced by Myc activation in the villin-MycERTAM mice. Paneth
cells reside at the base of the crypt and may be identified by
antilysozyme staining. Activation of Myc induced the loss of
lysozyme immunoreactivity (Fig. 4A to D), although more
slowly and less completely than the loss of Alcian blue staining:
even after 3 days of sustained Myc activation, strongly ly-
sozyme-positive cells still remained in a few crypts (Fig. 4D).
This sporadic disappearance of Paneth cells is most consistent
with their loss by apoptosis, which occurs at significant rates
within the crypt. Indeed, a detailed analysis revealed sporadic
coincident staining for Paneth cell lysozyme and TUNEL fol-
lowing MycERTAM activation, confirming that Myc-dependent
Paneth cell apoptosis does indeed occur (data not shown).
Using 5-HT (Fig. 4E to H), chromogranin A, and synaptophy-
sin (data not shown) staining to identify intestinal enteroen-
docrine cells, we observed no detectable change in the relative
levels or distribution of enteroendocrine cells following Myc
activation. Hence, direct activation of Myc affects the different
secretory cell compartments of intestinal epithelium in distinct
ways. Of note, the phenotype induced by direct Myc activation
is clearly distinct from that induced by deregulated -catenin
signaling.
Activation of oncogenes typically triggers growth-suppres-
FIG. 2. Myc activation induces rapid expansion of the proliferative crypt compartment together with increased crypt cell apoptosis. villin-
MycERTAM mice were treated either with control vehicle for 2 days (A and D) or with tamoxifen (tam) for 1 (B and E) or 2 (C and F) days. (A
to C) S-phase cells were labeled with BrdU administered systemically 3.5 h prior to sacrifice, and incorporated BrdU was detected by immuno-
fluorescence (BrdU in green, Hoechst counterstain in red). Myc activation induces a dramatic increase in the number of S-phase cells in each crypt,
expanding the proliferative zone. (D to F) Significant induction of apoptosis in the crypt was also observed following Myc activation, as indicated
by TUNEL staining (TUNEL in green, Hoechst stain in red).
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sive pathways, an evolutionary adaptation to neoplastic risk
dubbed intrinsic tumor suppression (29) that, in the case of
Myc, appears to be expressed principally through the induction
of apoptosis (2, 11, 41). How cells discriminate between nor-
mal and oncogenic signaling is unclear, although engagement
of intrinsic tumor suppression appears to require significantly
higher levels of Myc than does proliferation (36). Hence, one
possible reason for the differing phenotypes induced by direct
Myc activation versus its indirect activation via deregulated
Wnt/-catenin signaling could be different levels of Myc in
each case engaging intrinsic tumor suppression with differing
efficiencies. Thus, Myc represses expression of p21cip1 directly
through complexes comprising Myc and Miz1 (52) or indirectly
through induction of AP4 (19). Consistent with this, the mito-
genic signal elicited by -catenin suppresses p21cip1 expression
(20, 61). However, high levels of Myc can also engage the
ARF/p53 pathway (67), which potently induces expression of
p21cip1 (21). We therefore asked which of these Myc outputs
prevails following Myc activation in villin-MycERTAM mice.
Acute activation of Myc strongly induced p19ARF mRNA in
intestinal epithelium (Fig. 5A), and this was accompanied by
accumulation of both p53 and p21cip1 proteins (Fig. 5B). Acute
oncogenic stress has also been reported to activate p53 via the
induction of DNA damage, at least in vitro. We therefore
assessed induction of DNA damage foci following Myc activa-
tion by staining intestinal tissue sections for -H2.AX. How-
ever, Myc activation induced only a few, sporadic -H2.AX
foci (Fig. 5B) that showed no correlation with the widespread
stabilization of p53 and p21cip1. Hence, Myc activates the p53
pathway in villin-MycERTAM mice through direct induction of
p19ARF and not indirectly by inducing DNA damage. To assess
levels of expression of MycERTAM relative to that of endoge-
FIG. 3. Myc activation induces rapid loss of goblet cells. villin-MycERTAM mice were treated either with control vehicle for 2 days (A and D)
or with tamoxifen (tam) for 2 or 3 days (B, C, E, and F). (B and C) Goblet cell mucopolysaccharides were identified by Alcian blue staining, and
cell nuclei were counterstained with fast red. Alcian blue-positive goblet cells disappeared rapidly and synchronously throughout the crypt-villus
axis following MycERTAM activation. (E and F) Similar rapid and synchronous disappearance of Alcian blue-positive goblet cells was observed
throughout the large intestine crypts.
FIG. 4. Myc activation induces rapid loss of Paneth but not enteroendocrine cells. (A to D) Paneth cells, identified by immunofluorescence
staining for lysozyme (in green; Hoechst counterstain in red), disappeared rapidly but sporadically during 3 days of Myc activation. (E to H)
Enteroendocrine cells, identified by anti-5-HT immunostaining, were largely unaffected by Myc activation (5-HT staining in green, Hoechst
counterstaining in red). tam, tamoxifen.
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nous c-myc in normal intestinal epithelia of villin-MycERTAM
mice, we used quantitative real-time PCR. MycERTAM mRNA
was expressed around 40-fold higher than endogenous c-myc
mRNA (data not shown) and around 5-fold higher than the
elevated level of endogenous Myc induced by the loss of APC
(51). Evidently, MycERTAM is expressed at levels sufficiently
high to engage ARF/p53, overriding any direct repression of
the p21cip1 gene that Myc normally affords.
The biological effects of Myc overexpression and deregula-
tion in the intestinal epithelia of villin-MycERTAM mice are
rapidly reversed upon withdrawal of tamoxifen. The high in-
cidence of Myc overexpression in colonic adenocarcinoma (10,
13, 22, 30), together with its clear role as a mediator of -cate-
nin signaling, makes inhibition of Myc an attractive strategy for
treating colorectal cancers. However, while inactivation of on-
cogenic Myc restores normal tissue architecture in some cases
(41, 42), in some tissues its effects are irreversible, perhaps due
to permanent perturbation of the stem cell compartment (1).
To ascertain the consequences of subsequent deactivation of
MycERTAM in intestinal epithelium, MycERTAM was activated
for 4 days in villin-MycERTAM mice and then tamoxifen treat-
ment was stopped, leading to MycERTAM deactivation after
24 h (41, 42, 54). Following tamoxifen surcease, mice rapidly
regained weight. Dissection revealed refilling of intestines, in-
dicating the resumption of normal digestive function (cf. Fig.
6A and Fig. 1A). By 2 days after tamoxifen withdrawal, intes-
tinal architecture was still demonstrably aberrant (Fig. 6B), but
by 4 days after tamoxifen withdrawal, crypt-villus units ap-
peared normal, with normal cellular morphology and an epi-
thelial layer once again properly attached to the underlying
stroma (Fig. 6B). BrdU incorporation analysis indicated pro-
gressive shrinkage of the proliferative zone down toward the
crypt (Fig. 6B). Myc deactivation was also accompanied by
de-engagement of the ARF/p53/p21cip1 pathway, as evidenced
by the loss of p21cip1 staining (data not shown) and p19ARF
expression (Fig. 5A) and a significant decline in crypt cell
apoptosis (data not shown). Myc deactivation triggered a rapid
and synchronous reappearance of Alcian blue-positive cells,
which were distributed sporadically throughout the crypt-villus
axis (Fig. 7A to D). Likewise, cells positive for the goblet cell
marker Muc2 reappeared throughout the intestinal layer, in-
cluding high up the villus, within only 24 h of Myc deactivation
(Fig. 8). Such rapid reemergence in the distal villus strongly
supports the notion that the reappearance of goblet cells is due
to redifferentiation of cells in situ rather than vectorial repopu-
lation from the crypt base. Strongly lysozyme-positive Paneth
cells also reappeared rapidly following Myc inactivation (Fig.
7E to H), although not in all crypts, with some remaining
devoid of Paneth cells even after 4 days.
DISCUSSION
Deregulation of the Wnt/-catenin pathway is implicated in
the majority of human colorectal cancers, where it appears to
be critical in initiating the formation of polyps, the benign
precursors of colorectal cancer. Studies indicate that deregu-
lated Wnt/-catenin locks crypt stem and progenitor cells in
their proliferative and undifferentiated states, in great part
through sustained actions of the TCF-4 transcription factor.
More recently, the pleiotropic bHLHZip transcription factor
Myc has been implicated as a key, obligate downstream effec-
tor of Wnt/-catenin signaling. Myc is induced by Wnt/-cate-
nin signals, and its acute loss triggers abrupt growth arrest
within the proliferating crypt compartment (35, 57). Moreover,
acute Myc deletion forestalls the induction of the majority of
Wnt/-catenin target genes and abrogates the pathological and
FIG. 5. Activation of Myc in intestinal epithelium of villin-MycERTAM
mice triggers the ARF/p53/p21cip1 tumor suppressor pathway. (A) Real-
time quantitative PCR analysis of ARF (p19ARF mRNA) expression in
intestinal epithelia of nontransgenic control mice treated with tamox-
ifen (tam) versus that in villin-MycERTAM mice treated with the vehicle
control (oil) or tamoxifen for 3 days (tam 3d). Myc activation triggers
strong induction of ARF, which is lost upon MycERTAM deactivation
for 3 days (Off 3d). (B) Immunofluorescence staining for p53, p21cip1,
and phospho-H2.AX (in green, Hoechst nuclear counterstain in red)
in intestinal epithelia of villin-MycERTAM mice treated with either the
vehicle control or tamoxifen for 3 days. Myc activation rapidly induced
accumulation of both p53 and p21cip1. In contrast, anti-phospho-
H2.AX staining (a marker of DNA damage) showed only very occa-
sional foci following Myc activation (yellow arrowheads) that may be
attributable merely to normal mitosis (14). Hence, widespread p53 and
p21cip1 induction occurs without concomitant evidence of widespread
DNA damage.
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oncogenic impact of Wnt/-catenin deregulation on intestinal
epithelium (50). However, while endogenous Myc function is
required for much of the biological output of Wnt--catenin
signaling in intestinal epithelium, the extent to which Myc
alone can substitute for Wnt/-catenin signaling is unclear. To
investigate this directly, we employed a transgenic approach in
which the reversibly switchable variant of Myc, MycERTAM,
was targeted to intestinal epithelium. Whereas excision of
floxed APC (35, 50) is incomplete and irreversible and takes
several days to achieve high-efficiency deletion of APC, sys-
temic administration of tamoxifen activates MycERTAM rap-
idly (2 h), synchronously, ubiquitously, and reversibly in tar-
get tissues (27). This makes it possible to ascertain the direct
and immediate consequences of abrupt Myc activity in vivo.
Direct activation of Myc in intestinal epithelium induced rapid
phenotypic changes that overlapped with, but were not iden-
tical to, those induced by deregulation of -catenin signaling.
Thus, as with the acute loss of APC, acute Myc activation
FIG. 6. The Myc-induced phenotype in villin-MycERTAM mice is reversible following MycERTAM deactivation. Myc was activated for 4 days in
villin-MycERTAM mice and tamoxifen, then withdrawn for 4 days to deactivate MycERTAM. MycERTAM deactivation triggered rapid refilling of the
intestine (A) together with rapid return to normal intestinal architecture and shrinkage of the proliferative compartment back to its normal size
and location in the intestinal crypts (B) (BrdU in green, Hoechst counterstaining in red). H&E, hematoxylin and eosin.
FIG. 7. Myc deactivation in villin-MycERTAM mice induces rapid restoration of both goblet and Paneth cell compartments. villin-MycERTAM
mice were treated with tamoxifen for 4 days to activate Myc, and then the treatment was withdrawn for 1 to 4 days, as indicated. (A to D) Sections
of small intestine were stained with Alcian blue or antilysozyme antibody (lysozyme in green, Hoechst counterstain in red). Alcian blue-positive
goblet cells reappear synchronously throughout the crypt-villus axis by 2 to 4 days after Myc deactivation. (E to H) Lysozyme-positive Paneth cells
also reappeared over a similar time frame but more sporadically.
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induced the loss of goblet cells. Of note, Myc-induced goblet
cell loss was both rapid and synchronous, occurring throughout
the epithelial layer irrespective of position within crypts or villi.
Such synchronous loss is difficult to reconcile with the notion
that goblet cell depletion results from failure to replenish these
cells at the crypt together with their upward migration and loss
at the villus tip. In the absence of any observable goblet cell
apoptosis, in situ dedifferentiation seems the most likely mech-
anism, a notion confirmed by the similarly abrupt and synchro-
nous reappearance of goblet cell markers throughout the epi-
thelium shortly after Myc was deactivated. Terminal secretory
cell fate in the intestinal epithelium is determined by Notch
signaling, whereas the Wnt pathway regulates the emergence
of cells from the cryptal stem cell and transit-amplifying com-
partment. Hitherto, the lack of differentiated cells caused by
overactivity of the Wnt/-catenin pathway was thought to be a
consequence of retention of cells in a crypt-like state, prevent-
ing their emergence into the Notch-regulated compartment.
However, the in situ dedifferentiation of goblet cells that we
observed suggests that Myc can override and reverse estab-
lished Notch-dependent terminal differentiation, indicating a
novel potential cross talk between the Wnt/-catenin and
Notch pathways.
Wnt/-catenin signaling is required for Paneth cell matura-
tion (62), at least in part through induction of the Sox9 tran-
scription factor (33), while another Wnt/-catenin target,
EphB3, is required for their localization to the bottom of the
intestinal crypts (6, 7). Acute deregulation of Wnt/-catenin
signaling by APC loss induces mislocalization of Paneth cells
within the crypts (51), probably as a consequence of gross
expansion of the crypt progenitor compartment and perturba-
tion of the interplay between EphB3 and another Wnt/-cate-
nin target, EphB2, which together govern migration and local-
ization of cells along the crypt-villus axis. In contrast, direct
Myc activation in intestinal epithelium caused rapid ablation of
Paneth cells, apparently by apoptosis. This is perhaps surpris-
ing, given that Wnt/-catenin-dependent induction of both
EphB2 and EphB3 is dependent on endogenous Myc (50). On
the other hand, Sox9, necessary for Paneth cell genesis, is one
of the small number of Wnt/-catenin targets whose induction
is not dependent on endogenous Myc (50). Furthermore, while
upregulation of EphB3 by APC loss may indeed depend on
endogenous Myc, EphB3 is not itself a Myc target. Thus, Pa-
neth cells are impacted by Myc very differently when it is
activated directly from when it is activated indirectly in the
context of Wnt/-catenin signaling.
Identification of Myc as a key mediator of aberrant Wnt/-
catenin signaling underscores its importance as a conduit for
oncogenic signaling in this tissue and indicates that the inhibi-
tion of Myc might be an effective strategy for therapeutic
intervention, as it is for Ras-driven tumorigenesis in the lung
(57). Nonetheless, the distinct impacts of constitutive Wnt/-
catenin signaling and directly activated Myc on the fate of
Paneth cells indicate that a simple sequential model in which
APC loss induces endogenous Myc, which is then solely re-
sponsible for the transcriptional impact of deregulated Wnt/-
catenin signaling, is overly simplistic.
There are several plausible reasons why direct activation of
Myc fails to substitute for deregulated Wnt/-catenin signal-
ing. First, as exemplified by Sox9 in intestine, some genes
induced by Wnt/-catenin are Myc independent (50) and me-
diate Myc-independent biological outputs. This is dramatically
illustrated by what occurs in liver, where endogenous Myc
appears completely dispensable for the hyperproliferative phe-
notype induced by APC inactivation (46). Second, while en-
dogenous Myc activity may be needed for Wnt/-catenin-de-
pendent expression of some genes, this does not necessarily
imply that Myc is the transcription factor directly responsible
for their induction. Myc is a highly pleiotropic and context-
dependent transcriptional modulator. By acting as a general
modulator of global chromatin structure (24), Myc may act as
a permissivity factor that dictates whether or not certain genes
are available for induction by other transcription factors. Such
a relationship is consistent with the remarkably scant overlap
between known Myc targets and genes regulated by Wnt. In-
deed, our own analysis of SOX17, Axin2, Tiam1, and Tcf1, four
representative target genes that are induced by APC loss in
intestine in a Myc-dependent manner (50), indicates that none
is induced by direct Myc activation alone (not shown). Third,
Myc is activated by many other pathways besides Wnt/-cate-
nin, including RTK/Ras signaling and Notch, that have the
potential to modulate or even annul Wnt/-catenin output.
Last, certain attributes of Myc may be manifest only when Myc
itself is directly activated, rendering it refractory to regulatory
influences that limit endogenous Myc, even when driven by
deregulated Wnt/-catenin signals. For example, directly acti-
vated Myc has been shown to positively reinforce Wnt/-cate-
nin signaling in some tissues through suppression of the Wnt
inhibitors DKK1 and SFRP1 (9) and induction of the Wnt
ligand Fzd9 (27) (although this does not occur in intestinal
epithelium; direct Myc activation induces no measurable trans-
location of -catenin to the nucleus [data not shown]). An-
FIG. 8. Myc deactivation in villin-MycERTAM mice induces rapid reappearance of goblet cells throughout the epithelium. villin-MycERTAM mice
were treated with tamoxifen for 4 days to activate Myc and tamoxifen, and then the treatment was withdrawn for 3 days, as indicated. Sections of
small intestine were stained for the intestinal mucin goblet cell marker Muc2. Muc2-positive goblet cells reappeared throughout the crypt-villus
axis by 2 to 4 days after Myc deactivation.
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other outcome largely peculiar to directly activated Myc is
engagement of the ARF/p53 pathway, which occurs only when
Myc is expressed above certain threshold levels that engage the
cell’s intrinsic tumor surveillance programs (36). Expression of
the Cdk inhibitor p21cip1 exemplifies two diametrically op-
posing possible outcomes of Myc activation in intestinal
epithelium. Myc represses expression of p21cip1 through well-
described mechanisms involving association with the transcrip-
tional repressors Miz1 and Dnmt3 (8, 52, 63) and induction of
AP4 (19). However, oncogenic Myc can also activate the p53
pathway, which potently induces p21cip (12, 67). When indi-
rectly activated by deregulated Wnt/-catenin signaling in in-
testine, Myc suppresses p21cip1 expression (50), presumably
accounting for the negligible impact of p53 status on the ab-
errant proliferation induced by APC inactivation (47). In con-
trast, when directly activated in villin-MycERTAM mice, Myc
engages the p53 pathway and potently induces p21cip1. The
difference is most likely due to the significantly higher levels of
Myc present in intestinal epithelial cells of villin-MycERTAM
mice than those in APC-deficient epithelium, levels that
breach the higher threshold required for p53 pathway activa-
tion (36).
Our data offer a compelling explanation for why it is that
Myc, a potent oncogene and activator of multiple intra- and
extracellular proliferative programs, is directly activated by
gene amplification or rearrangement only relatively infre-
quently in patients with colorectal cancer and then only in
more-advanced and metastatic stages of the disease. Colorec-
tal tumorigenesis is initiated when deregulated Wnt/-catenin
signals lock crypt stem and progenitor cells in their prolifera-
tive and undifferentiated states. Although this requires Myc,
Myc-independent functions of Wnt/-catenin exist, and some
of these may be critical for intestinal tumorigenesis. Further-
more, whereas direct activation of Myc triggers intrinsic tumor
suppression, Myc activated indirectly by Wnt/-catenin signal-
ing fails to, allowing incipient intestinal tumors to evade tumor
surveillance until such time as the p53 pathway has become
eroded by happenstance and directly activated Myc is tolerable
by the emerging colorectal tumor.
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